Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Inclusion Criteria:

• De novo and primary Ph/BCR-ABL1 negative acute lymphoblastic leukemia diagnosed bythe bone marrow cytomorphology, immunophenotyping, cytogenetics and molecularbiology according to WHO classification

• Age: 14 -60 years

• Male or female

• ECOG Performance Status 0-2

• Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit ofnormal（ULN）; serum alanine aminotransferase (ALT) and serum aspartateaminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liveris present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkalinephosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes:Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasoundejection fraction ≥ 45%;

• Subject has provided written informed consent prior to any screening procedure

Exclusion Criteria:

• Burkitt lymphoma/leukemia

• Acute Leukemia of Ambiguous Lineage

• Female patients who are pregnant or breast feeding

• Uncontrolled active serious infections that could, in the investigator's opinion,potentially interfere with the completion of treatment

• History of pancreatitis

• Poorly controlled diabetes, defined as glycosylated hemoglobin (HbA1c) values of >7.5%. Patients with preexisting, well-controlled diabetes are not excluded

• History of active gastrointestinal bleeding within the last 6 months

• History of arterial/venous thrombosis within the last 6 months

• Known HIV seropositivity

• Any serious psychiatric illness that could, in the investigator's opinion,potentially interfere with the completion of treatment